dc.contributor.author | ORHAN, OKAN | |
dc.contributor.author | Kilciksiz, Sevil | |
dc.contributor.author | Celik, Omur Karakoyun | |
dc.contributor.author | PAK, YÜCEL | |
dc.contributor.author | DEMİRAL, AYŞE NUR | |
dc.contributor.author | Pehilvan, Mustafa | |
dc.contributor.author | Haydaroglu, Ayfer | |
dc.contributor.author | Agaoglu, Fulya | |
dc.contributor.author | Tokatli, Fusun | |
dc.contributor.author | Zincircioglu, Burhanedtin | |
dc.contributor.author | ATASOY, BESTE MELEK | |
dc.contributor.author | Ozseker, Naciye | |
dc.contributor.author | Yersal, Ozlem | |
dc.contributor.author | Niang, Umar | |
dc.date.accessioned | 2021-03-05T20:04:20Z | |
dc.date.available | 2021-03-05T20:04:20Z | |
dc.date.issued | 2008 | |
dc.identifier.citation | Kilciksiz S., Celik O. K. , PAK Y., DEMİRAL A. N. , Pehilvan M., ORHAN O., Tokatli F., Agaoglu F., Zincircioglu B., ATASOY B. M. , et al., "Clinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group-Sarcoma Working Party", AMERICAN JOURNAL OF HEMATOLOGY, cilt.83, ss.702-707, 2008 | |
dc.identifier.issn | 0361-8609 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_d244405b-96fd-443d-bd68-39bb73ad9f15 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/138924 | |
dc.identifier.uri | https://doi.org/10.1002/ajh.21211 | |
dc.description.abstract | To identify the outcomes of prognostic factors of solitary plasmacytoma mainly treated with local radiotherapy (FIT). The data were collected from 80 patients with solitary plasmacytoma (SP). Forty patients (50.0%) received radiotherapy (FIT) alone while 38 of them (47.5%) were treated with surgery (S) and FIT. The median radiation dose was 46 Gy (range 30-64). The median follow up was 2.41 years (range 0.33-12.33). Ten-year overall survival (OS) and local relapse-free survival (LRFS) were 73% and 94%, respectively. The median progression-free survival (PFS) and multiple myeloma-free survival (MMFS) were 3.5 years and 4.8 years, respectively. On multivariate analyses, the favorable factors were radiotherapy dose of >= 50 Gy and RT + S for PFS and younger age for MMFS. For the patients with medullary plasmacytoma, the favorable factor was younger age for MMFS. RT at >= 50 Gy and RT + S may be favorable prognostic factors on PFS. Younger patients, especially with head-neck lesion and without pre-RT macroscopic tumor, seem to have the best outcome when treated with RT +/- S. Progression to MM remains as the main problem especially for older patients. | |
dc.language.iso | eng | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Hematoloji | |
dc.subject | HEMATOLOJİ | |
dc.title | Clinical and prognostic features of plasmacytomas: A multicenter study of Turkish Oncology Group-Sarcoma Working Party | |
dc.type | Makale | |
dc.relation.journal | AMERICAN JOURNAL OF HEMATOLOGY | |
dc.contributor.department | Gaziantep Üniversitesi , , | |
dc.identifier.volume | 83 | |
dc.identifier.issue | 9 | |
dc.identifier.startpage | 702 | |
dc.identifier.endpage | 707 | |
dc.contributor.firstauthorID | 189593 | |